Another week of new all-time highs for the Dow Jones Industrial Average coupled with a good start to earnings season has given optimists little reason to fret. For skeptics like me, that's an opportunity to see whether companies have earned their current valuations.
Keep in mind that some companies�deserve�their current valuations. Life sciences company Life Technologies�jumped to new highs this week following word that Thermo Fisher Scientific�will make a bid for the company, and that other private-equity firms are finalizing their bids.�With Life Technologies having publicly announced a strategic review in January, it seems like a long-awaited buyout could be right around the corner for shareholders.
Still, other companies might deserve a kick in the pants. Here's a look at three companies that could be worth selling.
Leave the wrapper on
The returns on confectioner Tootsie Roll Industries (NYSE: TR ) have certainly been sweet for investors over the past year. You have to go back to the summer of 2010 to find sugar prices that were as low as they are now,�which has played a good part in helping Tootsie Roll keep that aspect of its costs down. But taking a bigger view of what's going on with Tootsie Roll and comparing that to its current valuation creates a sour taste in my mouth.
Hot Telecom Stocks To Buy Right Now: Neuroderm Ltd (NDRM)
Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson�� disease (PD). The Company designs product candidates that address needs in the field of Parkinson�� disease and cognition. The Company�� product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. The Company developed a liquid formulation of levodopa/carbidopa (LD/CD). The Company through its reformulation technology develops a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. The Company�� LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson�� disease.
ND0612L for moderate Parkinson�� disease
ND0612L is under development for the treatment of moderate Parkinson�� disease patients who can no longer effectively control their motor complications with oral levodopa. ND0612L is developed as a fixed dose liquid formulation of levodopa and carbidopa to be administered subcutaneously, over a day and night period. The product ND0612L has two versions under development: ND0612L belt pump version, which is subcutaneously administrated via a small belt-pump, and ND0612L Patch Pump Version, which is a second generation product that is subcutaneously administrated via a patch pump.
The Company has conducted two Phase I studies and a Phase IIa clinical study with N0612L. The clinical studies was a single-dose, 24-hour continuous-administration, randomized, double-blind, placebo-controlled study on eight subjects with moderate Parkinson�� disease. The study results demonstrated that subcutaneous deli! very of ND0612L was safe and tolerable, and achieved steady-state plasma levodopa concentrations of 700-900 nanogram/milliliter. Additionally, administration of ND0612L was shown to significantly reduce fluctuations in plasma levodopa concentrations.
The Company is conducting a Phase II randomized, placebo-controlled, double-blind study of ND0612L on approximately 30 Parkinson�� disease patients suffering from motor complications. The study�� primary endpoints are safety and tolerability, as well as the pharmacokinetic profile of levodopa plasma concentrations.
ND0612H for severe Parkinson�� disease
The Company is developing ND0612H for the treatment of severe-stage Parkinson�� disease patients for whom oral drugs are no longer effective. The ND0612H belt pump (CRONO Twin ND) is a drug pump that delivers levodopa/carbidopa (LD/CD) to treat severe Parkinson�� disease patients. ND0612H provides continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to improve motor and non-motor complications in patients refractory to oral LD/CD. ND0612H�� is subcutaneously administrated utilizing a belt-pump allowing patients to receive continuous LD/CD therapy round the clock. The Company is conducting Phase II clinical trials on the product ND0612H for the treatment of severe-stage Parkinson�� disease.
ND0680 for severe Parkinson�� disease
ND0680 is indicated for the treatment of very severe Parkinson�� disease, which requires high doses of LD/CD which cannot be provided via oral delivery or using ND0612L and ND0612H. ND0680 is administered via a tube to the duodenum. ND0680 formulation contains a much higher concentration of LD/CD and is administered with the CRONO ND belt pump via the duodenum. The Company is conducting Phase I clinical trials for the development of ND0680
ND0701 for severe Parkinson�� disease
ND0701 is an apomorphine-based product candidate. ND0701 is desi! gned for ! the treatment of patients with severe Parkinson�� disease and do not respond well to LD/CD. ND0701 is administered via a CRONO ND belt pump or a patch pump (1st and 2nd generation, respectively). The Company is conducting Phase I clinical trials for the development of ND0701 indicated for the treatment of severe Parkinson�� disease.
ND0801 for Cognitive Disorders
ND0801 is under development for the treatment of cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer�� disease, Parkinson�� disease and schizophrenia. ND0801�� is covered by a reformulation and is designed to be a nicotine-based combination drug treatment. ND0801 is administered via a transdermal patch.
The Company is conducting tests on ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on approximately 45 adult patients. The study is designed to demonstrate the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801. Interim results from 30 patients enrolled have demonstrated a dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.
Advisors' Opinion:- [By Johanna Bennett]
NeuroDerm (NDRM) nearly doubled in value today, rising to $12.25 a share after more than 15 million shares changed hands, after the company reported positive results in a small trial for a treatment for Parkinson�� disease.
Top 5 Life Sciences Companies To Watch In Right Now: Blackrock Global (BOE)
BlackRock Global Opportunities Equity Trust is a closed ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets across the globe. The fund invests in the stocks of companies operating across diversified sectors. It primarily invests in all cap companies. The fund benchmarks the performance of its portfolio against the S&P Global Broad Market Index. BlackRock Global Opportunities Equity Trust was formed on May 31, 2005 and is domiciled in the United States.
Advisors' Opinion:- [By Michael Cintolo]
Diamondback Energy currently estimates its proved oil and natural gas reserves at 63.6 billion barrels of oil equivalent (BOE), but believes that figure could grow by another 393 million (BOE) as methods improve for extracting resources from shale oil fields.
Top 5 Life Sciences Companies To Watch In Right Now: Prima BioMed Ltd (PBMD)
Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates. Advisors' Opinion:- [By Bryan Murphy]
Were it the first time, or even the second time, it happened, it might be dismissible. A third time though? As they say, the third time is the charm. If the old saying applies in the worlds of small cap stocks (and it usually does), then Prima Biomed Ltd. (NASDAQ:PBMD) just kick-started what could be a trade-worthy rally.
Top 5 Life Sciences Companies To Watch In Right Now: Aceto Corporation(ACET)
Aceto Corporation engages in the sourcing, regulatory support, marketing, and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals worldwide. The company operates in three segments: Health Sciences, Specialty Chemicals, and Agricultural Protection Products. The Health Sciences segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. The Specialty Chemicals segment provides various chemicals used in plastics, surface coatings, textiles, fuels, and lubricants; organic intermediates used in the production of agrochemicals; and dye and pigment intermediates used in the color-producing industries, such as textiles, inks, paper, and coatings. This segment also offers diazos and couplers to the paper, film, and electronics industries. The Agricultural Protection Products segment sells herbicides, fungicides, insecticides, and other agricultural chemicals that control weed growth, as well as control the spread of insects and other microorganisms that can damage plant growth. This segment also provides sprout inhibitor for potatoes and an herbicide for sugar cane. It serves pharmaceutical, nutraceutical, agricultural, coatings, and industrial chemical consuming industries. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.
Advisors' Opinion:- [By Monica Gerson]
Aceto (NASDAQ: ACET) is projected to post its Q4 earnings at $0.17 per share on revenue of $134.23 million.
SeaChange International (NASDAQ: SEAC) is estimated to post a Q2 loss at $0.18 per share on revenue of $26.80 million.
No comments:
Post a Comment